Current stock page

Stock Analysis

MBX Biosciences, Inc. Common Stock (MBX) Stock Analysis

MBX Biosciences, Inc. Common Stock (MBX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

MBX Stock Analysis Summary

MBX Biosciences, Inc. Common Stock (MBX) currently has an AIQ Score of 68/100, indicating a bullish setup. Quality is the strongest factor at 74/100. Risk is the weakest current factor at 50/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

MBX at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$55.94
AIQ Score68/100
Overall ViewBullish
Technical Analysis ConsensusStrong Buy
Market Cap$2.72B
P/E Ratio (TTM)-18.28
Forward P/E—
EPS (Q3 FY2026)-$1.29
Revenue (Q3 FY2026)$0
Dividend Yield (TTM)0.00%
Beta1.26
Volume855.45K
52-week range$23.07-$72.64
RSI 1453.28
50-Day SMA$55.78
200-Day SMA$46.32
Analyst Price Target$106.67
Next EarningsMar 11, 2027
As of Nov 13, 2026 · Market close

MBXMBX Biosciences, Inc. Common Stock

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$55.94+$1.43 (+2.62%)

Latest quote

  • Momentum
    71
  • Value
    —
  • Quality
    74
  • Risk resilience
    50
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

MBX Stock Analysis Summary

MBX Biosciences, Inc. Common Stock (MBX) currently has an AIQ Score of 68/100, indicating a bullish setup. Quality is the strongest factor at 74/100. Risk resilience is the weakest current factor at 50/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bullish

In a bullish regime, MBX has AIQ Score of 68/100 with Quality base of 74/100 and fading Risk resilience at 50/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Quality (74/100) leads while Risk resilience (50/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 2.62% stock move · MBX classified in Biotechnology.

Current Evidence

BullishMBX is in a bullish AIQ regime; Quality is the strongest visible factor at 74/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is MBX Bullish or Bearish Right Now?

MBX currently has a bullish overall setup. Quality is the strongest factor at 74/100, while Risk Resilience is weakest at 50/100. The current evidence suggests a constructive setup.

Bull Case
  • - Quality is supportive at 74/100.
  • - Momentum is constructive at 71/100.
  • - Price is +0.29% above its 50-day SMA.
  • - Analyst target implies +90.68% upside from the latest quote.
  • - Technical consensus has more buy votes than sell votes (34 vs 4).
Bear Case
  • - No strong bearish evidence is available in the current snapshot.

Current Consensus

MBX's Technical Analysis Consensus is currently Strong Buy, with 34 buy, 8 neutral, and 4 sell votes. MBX's 14-day RSI is 53.28, which places the stock in a neutral momentum range. MBX's beta is 1.26, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in MBX?

The largest recent change in MBX is Momentum moving up by 4.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.

AIQ Score
+1.0
Momentum
+4.0
Quality
-1.0
Risk
+1.0

What Would Change the MBX Outlook?

The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

MBX Decision Framework

Public evidence layers, setup checks, and risk context for MBX Biosciences, Inc. Common Stock.

MBX Biosciences, Inc. Common Stock (MBX) Stock Analysis

MBX Biosciences, Inc. Common Stock has an AIQ Score of 68/100 in a Bullish regime. Quality is strongest at 74/100. Beta is 1.26, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextMBX is in a Bullish AIQ regime with score 68/100.
Signal ConflictThe primary conflict is that quality leads at 74/100 while risk lags at 50/100.
Factor EvidenceMomentum 71/100 · Quality 74/100 · Risk 50/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Quality is the strongest factor at 74/100.

TimingPass

Momentum is 71/100 and RSI (14) is 53.3.

Regime fitPass

MBX is in a Bullish regime at 68/100.

Risk controlWait

Risk factor is 50/100 with beta 1.26 and annual volatility 77.34%.

ConflictWait

Current conflict: quality leads at 74/100 while risk lags at 50/100.

AIQ Score
68/100
Price
$55.94
Beta
1.26
RSI (14)
53.3

MBX Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

MBX Fundamentals

MBX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$0
Net income
-$62.42M
Free cash flow
-$36.07M
View full MBX fundamental analysis

MBX Technical Analysis

MBX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
53.28
Price vs SMA-50
+0.29%
View full MBX technical analysis

MBX Stock Catalysts

Track MBX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Mar 11, 2027
Analyst target
$106.67
News items
0
View MBX earnings and stock catalysts

MBX Dividend Analysis

MBX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View MBX dividend history and analysis

MBX Financial Data

MBX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$0
EPS
-$1.29
Periods
8
View MBX financials

MBX Risk Analysis

MBX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.26
Risk score
50/100
1Y volatility
77.34%
View MBX risk analysis

MBX Stock News

MBX stock news, market tone, recent headlines, and catalyst context.

News items
0
Updated
—
Sentiment
—
Read MBX stock news

MBX vs Biotechnology Peers

Current peer cohort: MBX · MDGL · MIRM · MLYS · NAMS. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
MBX
Current stock
68/100—71/10050/1001.4277.34%Current
MDGL
Madrigal Pharmaceuticals, Inc.
57/10066/10040/10063/100-0.3242.57%MBX vs MDGL
MIRM
Mirum Pharmaceuticals, Inc.
53/10057/10054/10051/1000.7948.60%MBX vs MIRM
MLYS
Mineralys Therapeutics, Inc.
33/100—23/10035/100-1.4861.66%MBX vs MLYS
NAMS
NewAmsterdam Pharma Company N.V.
41/10042/10022/10048/100-0.9153.82%MBX vs NAMS
Pairwise Compare links: MDGL · MIRM · MLYS · NAMSMBX vs MDGLMBX vs MIRMMBX vs MLYSMBX vs NAMSCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a MBX stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for MBX: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-18.28
As of Nov 13, 2026
Revenue growth
—
Gross margin
0.00%
Current debt / equity
0.01
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$0
Quarter net income
-$62.42M
Quarter free cash flow
-$36.07M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bullish
Momentum
Mixed
RSI 14
53.28
MACD
0.07

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
50/100
Beta
1.26
Annual volatility
77.34%
Max drawdown
-37.60%

MBX Stock FAQ

What is MBX stock price today?

MBX Biosciences, Inc. Common Stock's current stock price is $55.94. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is MBX bullish or bearish right now?

MBX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is MBX's market cap?

MBX's market cap is $2.72B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is MBX's current P/E ratio?

MBX's current P/E ratio is -18.28 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is MBX's RSI?

MBX's 14-day RSI is 53.28 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is MBX above its 50-day and 200-day moving averages?

MBX is 0.29% from its 50-day SMA and 20.76% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is MBX's next earnings date?

MBX's next earnings date is currently listed as Mar 11, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does MBX pay a dividend?

MBX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.